A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Recurrent Oncogenic RAS Exon 2 Mutant Rectal Cancer
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs TG-02-Targovax (Primary) ; Pembrolizumab
- Indications Colorectal cancer
- Focus Adverse reactions; First in man
- Sponsors Targovax
- 02 Nov 2017 According to a Targovax ASA media release, interim data expected in 2H 2017 and clinical, immune and safety data in 2H 2018.
- 20 Apr 2017 According to a Targovax ASA media release, the first patient has been enrolled in this trial.
- 13 Oct 2016 Status changed from not yet recruiting to recruiting.